Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion

Description

Summary

This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).

Official Title

A Randomized, Double-blind, Placebo-controlled, Phase 2b Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Alcoholic Hepatitis

Keywords

Alcoholic Hepatitis acute alcoholic liver disease progressive inflammatory liver injury Hepatitis A Hepatitis Hepatitis, Alcoholic DUR-928 30 mg DUR-928 90 mg DUR-928 (30 mg) DUR-928 (90 mg)

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Able to provide written informed consent (either from subject or subject's legally acceptable representative)
  2. Onset of jaundice within prior 8 weeks
  3. Average daily consumption of >40 (females) or >60 (males) grams of alcohol for 6 months or longer, with < 8 weeks of abstinence before the onset of jaundice. Judgment regarding daily and long-term alcohol use and onset of jaundice will be made by the site investigator.
  4. Serum chemistry (as determined by local laboratory):
  5. Serum total bilirubin > 3.0 mg/dL
  6. 50 < AST < 400 IU/L
  7. ALT < 400 IU/L
  8. AST/ALT > 1.5
  9. Maddrey's discriminant function ≥ 32 assuming a control prothrombin time of 12 seconds
  10. Model for End-stage Liver Disease (MELD) score: 21-30
  11. When the diagnosis of AH remains in question, a liver biopsy (if clinically feasible and that subject has no contra-indications) will be required. Historical biopsy is allowed.
  12. Subjects must agree to use effective methods to prevent pregnancy while participating in the study.
  13. Subjects must agree to participate in an alcohol abstinence support program recommended by the local institution's addiction specialists

You CAN'T join if...

  1. Subjects taking corticosteroids for a duration exceeding 7 days in the 30 days prior to screening
  2. Subjects experiencing alcohol withdrawal symptoms or treatment with Clinical Institute Withdrawal Assessment for Alcohol (CIWA) protocol
  3. Active infection. Subjects who are febrile with leukocytosis are also excluded, even if there is no localizing diagnosis of infection.
  4. Serum creatinine >2.5 mg/dL or eGFR < 60 mL/min/1.73 m2
  5. Subjects with acute kidney injury (AKl) or Hepatorenal syndrome
  6. Subjects undergoing continuous veno-venous hemodialysis (CVVH)
  7. Uncontrolled active gastrointestinal bleeding
  8. Refractory ascites
  9. Liver biopsy (if carried out) with findings not compatible with AH
  10. . Stage ≥3 hepatic encephalopathy by West Haven criteria
  11. . Any severe concomitant cardiovascular, renal, endocrine, pulmonary, psychiatric disorder, or multi-organ failure
  12. . Other concomitant cause(s) of liver disease
  13. . Any active malignancies other than curatively treated skin cancer (basal cell or squamous cell carcinomas) or any other malignancy diagnosed within the last five years
  14. . Positive Urine Drug Screen (amphetamines, barbiturates, benzodiazepines, cocaine and opiates) except THC and prescription medications
  15. . Existing or intended pregnancy or breast feeding
  16. . Participation in another interventional clinical trial within 30 days of Screening
  17. . History of organ transplantation, other than a corneal transplant
  18. . Underlying diseases that, in the opinion of the site investigator, might be complicated or exacerbated by proposed treatments or might confound assessment of study drug

Locations

  • Site 38 not yet accepting patients
    San Francisco California 94143 United States
  • Site 24 accepting new patients
    Stanford California 94305 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Durect
ID
NCT04563026
Phase
Phase 2
Study Type
Interventional
Last Updated